Parallel Advisors LLC Boosts Stock Position in Agilent Technologies, Inc. $A

Parallel Advisors LLC increased its holdings in shares of Agilent Technologies, Inc. (NYSE:A) by 18.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,180 shares of the medical research company’s stock after buying an additional 948 shares during the period. Parallel Advisors LLC’s holdings in Agilent Technologies were worth $729,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Agilent Technologies by 13.5% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 36,674 shares of the medical research company’s stock worth $4,279,000 after purchasing an additional 4,362 shares during the last quarter. Assenagon Asset Management S.A. increased its position in shares of Agilent Technologies by 8.3% during the 1st quarter. Assenagon Asset Management S.A. now owns 30,827 shares of the medical research company’s stock worth $3,606,000 after purchasing an additional 2,371 shares during the last quarter. Alps Advisors Inc. lifted its holdings in shares of Agilent Technologies by 29.5% in the 1st quarter. Alps Advisors Inc. now owns 13,358 shares of the medical research company’s stock worth $1,563,000 after acquiring an additional 3,040 shares during the last quarter. D.A. Davidson & CO. boosted its holdings in Agilent Technologies by 30.4% during the 1st quarter. D.A. Davidson & CO. now owns 9,474 shares of the medical research company’s stock valued at $1,108,000 after acquiring an additional 2,207 shares during the period. Finally, LGT Capital Partners LTD. lifted its position in shares of Agilent Technologies by 7.6% during the first quarter. LGT Capital Partners LTD. now owns 768,252 shares of the medical research company’s stock worth $89,870,000 after purchasing an additional 54,302 shares in the last quarter.

Wall Street Analysts Forecast Growth

A has been the topic of several recent research reports. Barclays reaffirmed an “equal weight” rating and set a $125.00 target price on shares of Agilent Technologies in a research note on Friday, August 29th. TD Cowen lifted their target price on Agilent Technologies to $150.00 and gave the company a “buy” rating in a report on Thursday, May 29th. Wall Street Zen lowered Agilent Technologies from a “buy” rating to a “hold” rating in a report on Friday, September 5th. UBS Group dropped their target price on shares of Agilent Technologies from $150.00 to $130.00 and set a “neutral” rating on the stock in a research report on Thursday, May 29th. Finally, Wells Fargo & Company raised their target price on shares of Agilent Technologies from $140.00 to $150.00 and gave the stock an “overweight” rating in a research report on Monday. Six equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $140.08.

Insider Buying and Selling

In other news, CEO Padraig Mcdonnell sold 1,508 shares of the business’s stock in a transaction on Tuesday, July 1st. The stock was sold at an average price of $117.44, for a total value of $177,099.52. Following the completion of the transaction, the chief executive officer directly owned 37,448 shares of the company’s stock, valued at $4,397,893.12. The trade was a 3.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Agilent Technologies Stock Performance

A opened at $127.67 on Friday. The stock’s 50 day simple moving average is $120.19 and its 200 day simple moving average is $115.94. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.25 and a quick ratio of 1.71. The stock has a market cap of $36.19 billion, a P/E ratio of 29.97, a P/E/G ratio of 3.94 and a beta of 1.24. Agilent Technologies, Inc. has a 1-year low of $96.43 and a 1-year high of $153.84.

Agilent Technologies (NYSE:A) last posted its earnings results on Wednesday, August 27th. The medical research company reported $1.37 earnings per share for the quarter, meeting the consensus estimate of $1.37. The company had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.67 billion. Agilent Technologies had a return on equity of 25.51% and a net margin of 17.97%.Agilent Technologies’s revenue was up 10.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.32 earnings per share. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. As a group, equities analysts anticipate that Agilent Technologies, Inc. will post 5.58 EPS for the current fiscal year.

Agilent Technologies Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 22nd. Investors of record on Tuesday, September 30th will be paid a $0.248 dividend. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $0.99 dividend on an annualized basis and a yield of 0.8%. Agilent Technologies’s dividend payout ratio is presently 23.24%.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.